1488-96-6

Basic information

• Product Name: 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)
• Synonyms: 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)
• CAS NO: 1488-96-6
• Molecular Formula: C4H7N5O
• Molecular Weight: 141.13128
• Product Categories: VARIOUSAMINE
• Mol File: 1488-96-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.63g/cm³
• Refractive Index: 1.72
• CAS DataBase Reference: 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)(1488-96-6)
• EPA Substance Registry System: 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI)(1488-96-6)

Safety Data

• Hazardous Substances Data: 1488-96-6(Hazardous Substances Data)

Usage

General Description

1H-1,2,4-Triazole-1-carboxamide, 2-amino-N-methyl (9CI) is a chemical compound with the molecular formula C4H6N4O. It is a derivative of 1,2,4-triazole with an amide and amino groups. 1H-1,2,4-Triazole-1-carboxamide,2-amino-N-methyl-(9CI) has potential applications in pharmaceuticals and agricultural chemicals due to its unique chemical structure, which can be modified to create new drugs and pesticides. Its properties and reactivity make it an interesting compound for further research and development.

InChI:InChI=1/C4H7N5O/c1-6-4(10)9-3(5)7-2-8-9/h2H,1H3,(H,6,10)(H2,5,7,8)

Upstream product

• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 
• 624-83-9 methyl isocyanate 

Relevant articles and documents

-

-

Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia

In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1- [(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the airway through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1- [(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally (ip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD50 value of >2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D4 (LTD4) or platelet-activating factor (PAF)- induced responses. Taken together, these results suggest 23c as a novel candidate for the treatment of chronic asthma. Further studies are now underway.